Please assess the completion status of the following clinical trial:

Trial Title: Growth Hormone in Neuroendocrine Dysfunction With Severe Fibromyalgia Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women aged greater than or equal (\>=) 18 years~* Fibromyalgia diagnosed at least one year before~* History of generalized pain and at least 16 positive tender points (1990 American College of Rheumatology \[ACR\] criteria)~* Body Mass Index (BMI) less than or equal to(=\<) 32~* Normal GH stimulation test (insulin)~* Stable (\>= 3 months unchanged) standard treatment with amitriptyline (10-50 milligram per day \[mg/day\]) plus selective serotonin reuptake inhibitor (10-40 mg/day) plus tramadol (25-400 mg/day)~* Active rehabilitation program during the previous year (at least 30 minutes/day)~* Fibromyalgia Impact Questionnaire (FIQ) score \>=75~* IGF-1 serum level =\< 150 nanogram/milliliter (ng/mL) otherwise =\< 2 SD of the local lab normality)~* Normal response to IGF-1 generation test~* Chronic Fatigue Symptoms (Multidimensional Assessment of Fatigue \[MAF\])~* Effective anti-conception~* Willingness to comply with the protocol~* Written Informed consent~Exclusion Criteria:~* Major psychiatric condition~* Rheumatic disease, including systemic lupus erythematosus (SLE)~* Previous or current malignancies, active or inactive~* Clinical history intracranial space occupying lesion~* Reactive or secondary (rheumatoid arthritis \[RA\], osteoarthritis) fibromyalgia syndrome (FMS)~* Antinuclear antibody (ANA) greater than or equal 1:80~* Abnormal Creatine phosphokinase (CPK) or aldolase serum levels~* Not controlled thyroid disease in the last 3 months (free Thyroxine \[T4\] and Thyrotrophin-stimulating hormone \[TSH\] serum levels)~* Diabetes mellitus~* Adrenal gland disease (any abnormal cortisolemia, will be confirmed by 24-hour cortisoluria)~* Pregnancy or breast feeding~* Known to be hypersensitive to somatotropin or any of the excipients

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Saizen® (Type: ACTIVE_COMPARATOR): None
- Placebo + Saizen® (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).